The KIF1B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, engineered for loss-of-function studies of the KIF1B gene. This product contains a heterogeneous mix of cells with CRISPR/Cas9-mediated gene disruption of KIF1B, supplied as a knockout cell model for investigating KIF1B-dependent processes in intracellular transport, apoptosis, and tumor suppression.
The A-549 host cell line is a human alveolar type II-like lung adenocarcinoma epithelial line originally established from a 58-year-old Caucasian male. These cells are extensively used in cancer research due to their epithelial characteristics and relevance to lung adenocarcinoma biology, including drug response and metastatic studies. They provide a reproducible and well-characterized platform for examining the tumor-suppressive functions of KIF1B.
KIF1B encodes a kinesin motor protein that transports mitochondria and synaptic vesicles along microtubules in an ATP-dependent manner. It operates downstream of NGF signaling and the MAPK pathway, with transcriptional regulation by JUN and FOS. KIF1B interacts with DISC1 and 14-3-3 proteins, which modulate its cargo-binding and motor activity, while KIFBP and ARF6 further influence its localization and function. Critically, KIF1B regulates BAX-mediated apoptosis, establishing its role as a putative tumor suppressor. Through these interactions, KIF1B integrates extracellular cues with mitochondrial trafficking and cell death pathways.
Disruption of KIF1B in A-549 cells is expected to impair mitochondrial trafficking, leading to altered mitochondrial distribution and ATP production??factors that may influence tumor metabolic reprogramming. Loss of KIF1B also likely dysregulates BAX-mediated apoptosis, potentially conferring resistance to cell death and enhancing tumorigenicity. Thus, this knockout model allows dissection of KIF1B’s contributions to mitochondrial dynamics and apoptotic control in lung adenocarcinoma. The model may also inform studies on related pathologies such as Charcot-Marie-Tooth disease and neuroblastoma.
This polyclonal knockout population is suitable for Western blotting and RT-qPCR to assess KIF1B ablation and apoptosis marker expression. Immunofluorescence with MitoTracker probes enables visualization of mitochondrial morphology, while flow cytometry quantifies apoptosis and cell cycle changes. Transwell assays evaluate migration and invasion, and drug sensitivity testing reveals chemotherapeutic vulnerabilities in the absence of KIF1B. ATP measurement assays complement these approaches to assess mitochondrial function. For further technical inquiries or custom applications, contact Ascent Research.
